cyrilzakka/clinical-trials huggingface dataset:
Low Temperature Plasma Ablation Combined Lacrimal Duct Catheterization in the Treatment of Lacrimal Duct Obstructive

To compare the clinical effects of low temperature plasma ablation combined with lacrimal duct catheterization and YAG lacrimal duct laser combined with lacrimal duct catheterization in the treatment of lacrimal duct obstruction

Low-temperature plasma technology has developed rapidly in recent decades and is now widely used in ophthalmology, otolaryngology, orthopedics, urology and other fields .The low-temperature plasma surgery system relies on a 100kHz radio frequency electric field to excite normal saline (0.9% NaCl) to generate plasma energy, and relies on a 50-100 μm plasma layer generated at the front of the plasma knife to perform precise cutting, ablation and hemostaxy. But the application of this technique in the field of lacrimal duct still needs the accumulation of clinical experience.This study was aimed to compare the clinical effects of low temperature plasma ablation combined with lacrimal duct catheterization and YAG lacrimal duct laser combined with lacrimal duct catheterization in the treatment of lacrimal duct obstruction

Eligibility Criteria:
Inclusion Criteria:

* ① sign the informed consent for this study Voluntarily

  * ≥18 years old and \< 70 years old (3) Single lacrimal tract obstruction was included in the study

    * no purulent secretion of lacrimal passage

Exclusion Criteria:

* Patients who meet any of the following criteria will not be eligible for inclusion in this study:

  * Have a history of lacrimal duct surgery, including lacrimal duct catheterization, laser lacrimal duct plasty, etc

    * Have a history of allergy to hormones and antibiotics

      * congenital lacrimal duct malformation

        * nasal trauma and deformation ⑤ Patients with severe abnormal liver and kidney function and cardiovascular and cerebrovascular diseases In addition to lacrimal duct obstruction, there are other ophthalmic diseases ⑦ Exclude diabetes

          * Exclusion of pregnancy, lactation women ⑨ Not willing to participate in research
Sexual Health and Rehabilitation After Ovarian Suppression Treatment

This research study is evaluating an educational intervention for breast cancer survivors who have experienced changes in sexual function after ovarian suppression treatment to reduce the risk of breast cancer recurrence.

The purpose of this research is to study the effectiveness of an educational intervention for breast cancer survivors who have experienced changes in sexual function after ovarian suppression treatment to reduce the risk of cancer recurrence. The aim is to develop an effective intervention to help women manage these changes and restore sexual health and functioning.

- This study consists of attending a group educational session followed by a one-on-one telephone coaching session.

* The group educational session will last about 4 hours, and will include information on resources, self-help strategies, and relaxation techniques.
* The telephone coaching session will take place four weeks after the group session, and will last about 15 minutes

Eligibility Criteria:
Inclusion Criteria:

* Women with a history of breast cancer who are currently on chemical ovarian suppression
* Current age ≤ 50
* No active cancer therapy in the past 6 months and no future therapy planned
* Endorsement of at least one sexual symptom (see Appendix A for eligibility screening)
* English-speaking

Exclusion Criteria:

* History of pelvic radiation
* Prior participation in one of Dr. Bober's sexual health workshops
Performance Evaluation on the Upper Limb Closed Kinetic Chain Test After Scapular Elastic Taping on Jiu Jitsu Practitioners

Evaluate if the elastic tapping application on the scapular region can interferer immediately on the performance during the upper limb closed kinetic chain test on jiu jitsu practitioners.

Since the 2008 Olympic Games the elastic tapping has become popularized and used in many different professional and amateur practitioners of physical activity. However, the effects that their creators claim to have, the improvement of proprioception, muscular activity and pain has not yet been proved.

There is a lack of studies on the literature involving the using of elastic tapping and clinical functional tests, evaluating the differences on groups that where and where not submitted to the tape. The use of the bandage on healthy population has enhanced force sense in grip strength, and may increase the range of motion of the lower trunk. When applied on the triceps surae there was no increase on the height size of the jump task.

The purpose of this study is to analyze if the elastic tapping application on healthy practitioners of jiu jitsu can improve their performance on upper limb closed kinetic chain test.

It will be a randomized controlled trial with the CONSORT bases with 64 participants that will be divided into two groups:

* Control Group that will perform the upper limb closed kinetic chain test without any tapping and then tested again after applied a placebo tapping that will be placed vertically, against the orientation of the muscles that retrench the scapulas on the trunk.
* Intervention Group that will perform the upper limb closed kinetic chain test without any tapping and then tested again after applied a specific elastic tapping that is indicated to increase the activation of the lower and medium trapezius and the rhomboids, muscles responsible for retrench the scapula on the trunk.

The improvement of the test is upon the number of touches performed by the volunteer on a stated period of time (15 seconds). The best score of touches of three times trials will be taken as the mark of individuals of both groups, before and after utilizing the placebo and intervention kinesio tappings.

The investigators hypotheses is that after applying the tapping that improve the activation of the muscles of the scapulas, the practitioner will be able to improve the number of touches on the test.

Results will be expressed as hazard ratios (HR) with their respective confidence intervals at 95% and adopting α = 0.05. All analyzes will be performed by SPSS version 17.0.

Eligibility Criteria:
Inclusion Criteria:

* Practitioner of jiu jitsu for at least 12 months,
* No complain of pain on the upper limb on the last seven days.

Exclusion Criteria:

* Any episode of fracture on the upper limb (shoulder, elbow and wrist) on the last six months,
* To have any systemic inflammatory disease that restrains the subject of performing the test
Pre-recovery Bedside Liver Biopsy in Brain Death Organ Donors

This study's objective is to obtain preliminary data to test the hypotheses that percutaneous liver biopsy in brain death donors is safe and provides reliable histological information. Furthermore, that information when disseminated fully and widely many hours before organ recovery would not only decrease economic costs of wasteful recovery of livers that are not ultimately transplanted but also increase transplantation and decrease cold ischemia times of recovered livers.


Eligibility Criteria:
Inclusion Criteria:

* Neurological death donors in whom brain death determination is imminent
* First person or next of kin consent for research becomes available
* High risk donor, as defined by the following criteria i) Known liver disease ii) Hepatitis BsAg, BcAb, B DNA, Hepatitis C Ab or Hepatitis C RNA positivity iii) Age \>= 50 iv) Any of the following risk factors for fatty liver disease a) BMI \>= 30 b) History of Type 2 Diabetes Mellitus c) Ultrasound, Computerized Tomography or other imaging modalities suggesting steatosis v) Any of the following risk factors for chronic liver disease

  1. Greater than 2 drinks of alcohol daily currently or in their history
  2. Current IV drug use
  3. Ultrasound, Computerized Tomography or other imaging modalities suggesting cirrhosis

Exclusion Criteria:

* Donation after cardiac death donors
* Live organ donors
* No first person consent and next of kin decline research consent
* Donors in whom it has been established the liver will not be shared
* Donors in whom percutaneous liver biopsy has been performed within the past month for any indication and the biopsy results are available and considered reliable.
* Donor with a contraindication to liver biopsy, including INR \> 2, PTT \> 75, Platelets \< 70,000, history of coagulopathy, current or recent use (within 7 days) of antiplatelet agent such as aspirin or Plavix, and hemodynamic instability defined as a MAP less than 65mmHg.
* Inability to position donor appropriately for performance of PPB
* Unavailability of pathology staff to analyze specimen in a timely manner
Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

This study assessed the efficacy, safety, and pharmacokinetics of indacaterol salts (maleate, xinafoate and acetate) in patients with asthma.


Eligibility Criteria:
Inclusion Criteria:

* Non-smoker male and female adult patients aged 18-75 years inclusive, who have signed an informed consent form prior to initiation of any study-related procedure, including any adjustments to asthma medication prior to screening.
* Patients with asthma, receiving daily treatment with inhaled corticosteroid.
* Patients with a forced expiratory volume in 1 second (FEV1) during screening of ≥ 50% of the predicted normal value for the patient.
* Body mass index (BMI) must be within the range 18-32 kg/m\^2 (inclusive).
* Able to communicate well with the investigator and comply with the requirements of the study.

Exclusion criteria:

* A urine cotinine level greater than the local laboratory lowest level of quantification (LOQ of 500 ng/ml or lower).
* Patients who have had a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening.
* Patients who have had an emergency room visit for an asthma attack/exacerbation within 6 weeks prior to screening or any time between screening and pre-dose on day 1 of the study.
* Patients who have had a respiratory tract infection within 4 weeks prior to screening or any time between screening and pre-dose on day 1 of the study.
* Patients who require the use of ≥ 8 inhalations per day of the short-acting β2-agonist salbutamol/albuterol (100 μg/90 μg salbutamol/albuterol metered dose inhaler \[MDI\] or equivalent dose of a dry-powder inhaler \[DPI\]) on any 2 consecutive days from screening to randomization.
* Patients diagnosed with chronic obstructive pulmonary disease (COPD) as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (2008).
* Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. Previous participation in a study with either the investigational or comparator drugs does not exclude a patient from participation in this study.
* Significant illness.
* History of being immunocompromised, including a positive human immunodeficiency virus (HIV) test result (ELISA and Western blot).
* A positive hepatitis B surface antigen (HBsAg) or hepatitis C test result.
* Patients who are considered vulnerable as per ICH GCP guidelines.
* Patients with a history of hypersensitivity to indacaterol or to similar drugs including untoward reactions to sympathomimetic amines or inhaled medication or any component thereof.
* Treatments for asthma and allied conditions:
* The following treatments should not be used unless they have been stabilized prior to screening: antihistamines, inhaled nasal cromolyn, inhaled nasal corticosteroids, and maintenance immunotherapy.

Other protocol-defined inclusion/exclusion criteria applied to the study.
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.

This is the open-label extension to the open-label trials SP824 (NCT00242008), SP825 (NCT00243971), and SP826 (NCT00243945) that assessed the efficacy and safety and tolerability of rotigotine in subjects with idiopathic Parkinson's Disease.

Eligibility Criteria:
Inclusion Criteria:

* Subjects who have completed treatment in one of the SP824 (NCT00242008), SP825 (NCT00243971), or SP826 (NCT00243945) trials

Exclusion Criteria:

* Subjects who had an ongoing serious adverse event from the previous OLE trial that was assessed as related to study medication
Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer

Totally 60 subjects will be included in the study. The present study was aimed to observe and evaluate the effect of Xinmailong injection on reducing cardiovascular toxicity associated with adjuvant chemotherapy after breast cancer surgery. The primary endpoint was 6 months of cardiac safety. Secondary endpoints included 3 months of cardiac safety, adverse events (AE), severe adverse events (SAE), and DFS.

After signing the informed consent, the patients in the control group will receive Epirubicin 45mg/m2 d1, 2 + cyclophosphamide 600mg/ m2 d1, repeated every 14 or 21 days for 4 cycles, followed by paclitaxel 175 mg/m2 (or docetaxel 75 mg/m2) on day 1, repeated every 21 days for 4 cycles. Patients in the Xinmailong group were given 5 mg/kg of Xinmailong injection every cycle on d0, d1, d2, d3, d4 on the same chemotherapy regimen as those in the control group. The patients-general condition, vital signs, blood routine, liver and kidney function, electrocardiogram, myocardial enzymes, troponin, BNP and echocardiography should be examined every week. Breast ultrasound were performed every week. Chest CT were evaluated after 8 cycles of chemotherapy.

After adjuvant chemotherapy, adjuvant radiotherapy and endocrine therapy were given according to the situation, and long-term survival was observed.

The patients will be followed up for 5 years, once every 6 months with in 1-3 years, once every 12 months within 4-5 years.

Eligibility Criteria:
Inclusion Criteria:

1. age ≥18 years, female;
2. after radical mastectomy, EC - T adjuvant chemotherapy is planned.
3. No relevant treatment (such as antineoplastic therapy, immunotherapy, etc.) that may affect the outcome of treatment was received before admission.
4. ECOG PS score: 0-2 points;
5. Laboratory criteria:

   * white blood cells were more than 4 x 109 /L, and neutrophil count (ANC) was more than 1.5 x 109 /L.

     * platelet (\>100 \*109/L); hemoglobin (\>10g/dL); serum creatinine (\<1.5 \*normal value) upper limit (ULN); aspartate aminotransferase (AST) (\<2.5 \*ULN); alanine aminotransferase (ALT) (\<2.5 \*ULN); total bilirubin (\<1.5 \*ULN); serum creatinine (\<1.5 \*ULN); the volunteers voluntarily joined the study, signed informed consent, and had good compliance and follow-up.

Exclusion Criteria:

1. cockroach or xinmailong allergy (including xinmailong test positive).
2. Pregnant or lactation woman
3. severe bleeding tendency;
4. With mental disease
5. With severe infection or active gastrointestinal ulcers
6. allergic to chemotherapeutic agents;
7. Disease-free period of other malignant tumor is less than 5 years(except cured basal cell skin cancer and cervical carcinoma in situ).
8. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes
9. taking part or participating in other clinical trials within one month.
10. previous history of severe cardiovascular disease or cardiovascular disease risk factors were ≥ 4.
Impact of Different Instrument Modifications on Lateral Nasal Wall Osteotomy and Pterygomaxillary Separation in Le Fort I Surgery

The aim of this study is to investigate the effect of different instrument modifications on the customized osteotomy of the lateral nasal wall in Le Fort I surgery, focusing on the level of lateral nasal wall fractures and the separation pattern of the pterygomaxillary junction.

The primary hypothesis is blade osteotome is useful and facilitate the fracture line in ideal level both for lateral nasal wall and the pterygomaxillary junction.

While there are numerous studies in the literature evaluating various parameters related to maxillary down-fracture in Le Fort I osteotomy, studies specifically focused on lateral nasal osteotomy are very rare. There is no study in the literature has addressed customized lateral nasal osteotomy using different instruments. In our study, the lateral nasal wall osteotomy will be performed 2 mm shorter than the measured descending palatine ater distance in the axial computer tomography plane. One group (n=23) will use the routinely employed Nievert osteotome (single guided osteotome), while the other group (n=23) will use a blade osteotome (no guided tip). This study aims to evaluate parameters such as the fracture pattern of the lateral nasal walls and the separation pattern of the pterygomaxillary junction by using different instrument modifications for lateral nasal wall osteotomy.

Eligibility Criteria:
Inclusion Criteria:

* Patients requiring Le Fort I or bimaxillary surgery
* Patients who have not previously undergone Le Fort I or bimaxillary surgery (revision)
* Patients without cleft lip or palate
* Patients with no history of midface fractures or craniofacial trauma

Exclusion Criteria:

* Patients with cleft lip and/or palate requiring orthognathic surgery
* Patients with a history of trauma needing orthognathic surgery for malocclusion correction
* Patients who have previously undergone orthognathic surgery and require revision surgery
Trapeziectomy vs. Trapeziometacarpal Limited Excision for Thumb Base Osteoarthritis

A randomized comparison between trapeziectomy and trapeziometacarpal limited excision for thumb base osteoarthritis in 90 patients.


Eligibility Criteria:
Inclusion Criteria:

* Painful osteoarthritis in the thumb base and radiological arthritis (Eaton Littler class 2-3) and clinical signs of thumb base osteoarthritis (pain at palpation of the thumb base joint and pain during grinding test).
* Pain at rest.
* Conservative treatment \>6 months (activity modification, splinting, painkillers or thumb base steroid or PRP injection)

Exclusion Criteria:

* Rheumatoid arthritis.
* Ongoing infection in the hand or wrist. -
* History of gout or pseudo gout.
* Inability to co-operate with the follow-up protocol (language difficulties, severe psychiatric disorder, cognitive impairment, drug addiction).
* Intra-articular injection in the affected joint within 6 months.
* Eaton Littler class 4 (STT joint involved).
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors

TQB2618 is a TIM-3 receptor monoclonal antibody that binds to the extracellular domain of TIM-3 outside the cell to block the binding of TIM-3 to its ligand, thereby inhibiting the downstream signal transduction of TIM-3 and deactivating TIM-3 Inhibition of immune cells. The purpose of this study was to evaluate the safety, tolerability, pharmacokinetic parameters and antitumor effects of TQB2618 injection in subjects with advanced solid tumors.


Eligibility Criteria:
Inclusion Criteria:

* 1. Diagnosed as advanced malignant solid tumors and have failed standard treatments or lack effective treatments; 2. 18-75 years old; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; Life expectancy ≥12 weeks; 3. Has at least one measurable lesion; 4. The function of main organs is normal; 5. Female patients of childbearing age must be negative in serum or urine HCG within 7 days before enrollment in the study, and must be non-lactating; patients should agree to use contraceptive measures during the study period and within 6 months after the end of the study period; 6. Understood and signed an informed consent form.

Exclusion Criteria:

* 1. Has Autoimmune disease; 2. Has received allogeneic bone marrow transplantation or solid organ transplantation; 3. Has brain disease or brain metastases; 4. Has cavity effusion; 5. Has cardiovascular diseases; 6. Has immunodeficiency diseases; 7. Has liver disease; 8. Has infection; 9. Has diabetes; 10. Has a history of psychotropic drug abuse or have a mental disorder; 11. Have a history of severe allergy to macromolecular drugs or allergy to known components of TQB2618 injection; 12. Has other malignant tumors within 2 years before the first medication; 13. Has received other anti-cancer drugs or anti-cancer treatments, or major surgical operations within 4 weeks before the first medication; 14. Has received any live vaccines or vaccines to prevent infectious diseases within 4 weeks before the first medication; 15. Has received local radiotherapy within 1 week before the first medication; 16. Toxicity (excluding hair loss) caused by previous anti-tumor therapy that has not recovered to CTC AE V5.0 level 1 or below; 17. Has major wound, severe ulcer or fracture that has not healed before 1 day before the first medication; 18. Has used systemic hormones, immune agonists, inhibitors, and regulators before 1 day before the first medication; 19. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients

The purpose of this study is to asses the EED symptom prevalence in Koran GERD patients with typical reflux symptom and to evaluate quality of life with the scales including Gerd Q.


Eligibility Criteria:
Inclusion Criteria:

* GERD patients who have experienced heartburn or acid regurgitation during past 7 days
* GERD patients who have already undergone endoscopy before enrolment

Exclusion Criteria:

* Involvement in the planning and conduct of the programme
* The person who took the medicine such as PPI or H2RA during the last 7 days
* Severe systemic disease
Efficacy of Copper in Reducing Health-Acquired Infections in a Pediatric Intensive Care Unit

Healthcare-acquired infections (HAI) cause substantial patient morbidity and mortality. Commonly touched items in the patient care environment harbor microorganisms that may contribute to HAI risk. The purpose of this study is to assess whether placement of copper-alloy surfaced objects in a pediatric intensive care unit (PICU) reduce risk of HAI in comparison with non-copper surfaced objects.


Eligibility Criteria:
Inclusion Criteria:

* patient admitted to PICU
* stay at PICU \> 24 hours
* informed consent by parent/legal representative

Exclusion criteria: none